Want to see ZYBT full AI Analyst Report?
ZYBT Stock Chart & Stats
$1.13
--
Market closed
$1.13
--
Day’s Range― - ―
52-Week Range$0.62 - $13.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)871.70K
Market Cap
$22.95M
Enterprise Value$272.93M
Total Cash (Recent Filing)$51.89M
Total Debt (Recent Filing)$75.08M
Price to Earnings (P/E)―
Beta-0.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume198,467
30 Day Avg. Volume871,704
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.52
Price to Sales (P/S)3.27
P/FCF Ratio541.63
Enterprise Value/Market Cap11.89
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit41.08
Enterprise Value/Ebitda-6.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate Leverage / Equity CushionA relatively low debt-to-equity (~0.30) and sizable equity base provide a durable balance-sheet cushion. This reduces near-term refinancing pressure, preserves strategic optionality for R&D or restructuring, and supports runway while management works to restore profitability.
Positive Operating Cash FlowOperating cash flow remained positive (13.3M) despite a net loss, indicating underlying cash-generative aspects of the business. Sustained OCF is a structural strength that helps fund operations and limits immediate reliance on external financing while the company stabilizes revenues.
Historical Multi-year ProfitabilityPrior years of solid profitability demonstrate that the business model and cost structure can deliver healthy margins. That historical track record suggests the 2025 setback may be recoverable if demand, pricing, or cost issues are addressed and supports confidence in potential medium-term margin restoration.
Bears Say
Sustained Revenue DeclineA sharp multi-year revenue contraction significantly reduces scale economics, weakens bargaining power with suppliers/customers, and limits ability to absorb fixed costs. Persistent top-line decline undermines prospects for durable margin recovery and threatens long-term operational viability unless reversed.
Weak Free Cash Flow And ConversionFCF collapsed to near zero and OCF declined materially, producing volatile cash conversion. Thin free cash flow reduces capacity to fund capex, R&D, or acquisitions organically and raises the probability of needing external capital, which can dilute shareholders or increase leverage over the medium term.
Nasdaq Minimum Bid Price DeficiencyNon-compliance with Nasdaq minimum bid rules creates a structural listing risk. Management may need to pursue a reverse split or other actions, which can distract management, compress liquidity, and narrow the investor base; failure to cure could lead to delisting and constrained capital access.
Zhengye Biotechnology Holding Ltd. News
ZYBT FAQ
What was Zhengye Biotechnology Holding Ltd.’s price range in the past 12 months?
Zhengye Biotechnology Holding Ltd. lowest stock price was $0.61 and its highest was $13.08 in the past 12 months.
What is Zhengye Biotechnology Holding Ltd.’s market cap?
Zhengye Biotechnology Holding Ltd.’s market cap is $22.95M.
When is Zhengye Biotechnology Holding Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhengye Biotechnology Holding Ltd.’s earnings last quarter?
Currently, no data Available
Is Zhengye Biotechnology Holding Ltd. overvalued?
According to Wall Street analysts Zhengye Biotechnology Holding Ltd.’s price is currently Overvalued.
Does Zhengye Biotechnology Holding Ltd. pay dividends?
Zhengye Biotechnology Holding Ltd. does not currently pay dividends.
What is Zhengye Biotechnology Holding Ltd.’s EPS estimate?
Zhengye Biotechnology Holding Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhengye Biotechnology Holding Ltd. have?
Zhengye Biotechnology Holding Ltd. has 10,965,000 shares outstanding.
What happened to Zhengye Biotechnology Holding Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhengye Biotechnology Holding Ltd.?
Currently, no hedge funds are holding shares in ZYBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Technical Analysis
China Pharma Holdings
―
China SXT Pharmaceuticals
―
Qilian International Holding Group Limited
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
0.27% Mutual Funds
0.30% Other Institutional Investors
99.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---